Gary Lazar6850 Rosemead Blvd, San Gabriel, CA 91775

Gary Lazar Phones & Addresses

6850 Rosemead Blvd, San Gabriel, CA 91775

Social networks

Gary Lazar

Linkedin

Education

School / High School: Loyola University of Chicago / Stritch School of Medicine 1976

Mentions for Gary Lazar

Career records & work history

Medicine Doctors

Gary Lazar Photo 1

Dr. Gary S Lazar - MD (Doctor of Medicine)

Hospitals:
5342 Aldea Ave, Encino, CA 91316
Education:
Medical Schools
Loyola University of Chicago / Stritch School of Medicine
Graduated: 1976
Gary Lazar Photo 2

Gary Steven Lazar

Specialties:
Internal Medicine
Hematology
Medical Oncology
Hematology & Oncology
Education:
Loyola University Chicago (1976)

Gary Lazar resumes & CV records

Resumes

Gary Lazar Photo 20

Gary Lazar

Publications & IP owners

Us Patents

In Vivo Treatment Of Skin Lesions By Electrical Nanopulses

US Patent:
2013004, Feb 14, 2013
Filed:
Sep 28, 2012
Appl. No.:
13/631618
Inventors:
Alfred E. Mann Institute for Biomedical Engineerin - Los Angeles CA, US
Gary Steven Lazar - Encino CA, US
Doug Yin - Valencia CA, US
Assignee:
Alfred E. Mann Institute for Biomedical Engineering at the Univ. of Southern California - Los Angeles CA
International Classification:
A61N 1/05
US Classification:
607115
Abstract:
This disclosure relates to an in vivo treatment of a skin lesion of a mammal comprising application of electrical energy to the skin lesion in a form of electrical pulses. At least one electrical pulse is applied. The pulse duration may be at least 0.01 nanoseconds at the full-width-at-half-maximum. This treatment may at least prevent growth of the lesion.

Anti-Emp2 Therapy Reduces Cancer Stem Cells

US Patent:
2019007, Mar 14, 2019
Filed:
Feb 28, 2018
Appl. No.:
15/908269
Inventors:
- Oakland CA, US
- Encino CA, US
Lynn K. GORDON - Tarzana CA, US
Gary S. LAZAR - Encino CA, US
International Classification:
C07K 16/18
C07K 16/30
A61K 39/395
G01N 33/574
C07K 16/22
C07K 16/28
A61K 45/06
A61K 47/68
A61K 39/00
Abstract:
Reduction of EMP2 expression and/or anti-EMP2 therapy reduces cancer stem cells in multiple types of cancer. For example, breast cancers stem cells were defined by the presence of HIF-1α, CD44 and ALDH. It is found that anti-EMP2 IgG1 can be used to reduce the numbers of cancer stem cells.

Vivo Treatment Of Skin Lesions By Electrical Nanopulses

US Patent:
2018000, Jan 4, 2018
Filed:
Aug 11, 2017
Appl. No.:
15/675623
Inventors:
- Hayward CA, US
Gary Steven Lazar - Encino CA, US
Dong Yin - Valencia CA, US
Assignee:
Pulse Biosciences, Inc. - Hayward CA
International Classification:
A61N 1/05
C12N 13/00
A61N 1/32
H03K 3/53
A61B 18/14
A61B 18/00
A61B 18/12
Abstract:
This disclosure relates to an in vivo treatment of a skin lesion of a mammal comprising application of electrical energy to the skin lesion in a form of electrical pulses. At least one electrical pulse is applied. The pulse duration may be at least 0.01 nanoseconds at the full-width-at-half-maximum. This treatment may at least prevent growth of the lesion.

Anti-Emp2 Therapy Reduces Cancer Stem Cells

US Patent:
2015032, Nov 19, 2015
Filed:
Mar 14, 2013
Appl. No.:
14/389098
Inventors:
- Oakland CA, US
- Encino CA, US
Lynn K. GORDON - Tarzana CA, US
Gary S. LAZAR - Encino CA, US
International Classification:
C07K 16/18
A61K 39/395
G01N 33/574
C07K 16/30
C07K 16/22
A61K 47/48
A61K 45/06
C07K 16/28
Abstract:
Reduction of EMP2 expression and/or anti-EMP2 therapy reduces cancer stem cells in multiple types of cancer. For example, breast cancers stem cells were defined by the presence of HIF-1α, CD44 and ALDH. It is found that anti-EMP2 IgG1 can be used to reduce the numbers of cancer stem cells.

NOTICE: You may not use PeopleBackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. PeopleBackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.